Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01424345 · ClinicalTrials.gov registry record · Phase 4
The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient
A Phase 4 study, sponsored by CAMC Health System.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT01424345 is a Phase 4 study that was terminated before completion, run by CAMC Health System. The registered enrollment target is 4 participants.
The verdict
NCT01424345, a Phase 4 study, was terminated before completion, sponsored by CAMC Health System.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate whether there are any outcome benefits of a serial ImmuKnow assays in the management of de novo renal transplant recipients.
Interventions
- DRUG adjustment of immunosuppressant dosages
- DRUG adjustment of the dosages of immunosuppressants
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-12 |
| Est. Completion | 2012-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01424345
The ClinicalTrials.gov registry entry for NCT01424345 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CAMC Health System, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which adjustment of immunosuppressant dosages is the first listed.
NCT01424345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01424345 about?
NCT01424345 is a clinical study titled "The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient". The purpose of this study is to demonstrate whether there are any outcome benefits of a serial ImmuKnow assays in the management of de novo renal transplant recipients.
What is the current status of trial NCT01424345?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2011-12. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01424345?
The interventions under investigation include: adjustment of immunosuppressant dosages (DRUG), adjustment of the dosages of immunosuppressants (DRUG).
Who is sponsoring clinical trial NCT01424345?
This trial is sponsored by CAMC Health System, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.